Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 34 Issue 11, November 2016

Colored scanning electron micrograph of a colon cancer stem cell. Image credit: Martin Oeggerli / Micronaut, supported by School of Life Sciences, FHNW

Editorial

  • Advertisement

  • The US Food and Drug Administration approved a muscular-dystrophy drug against the scientific advice of its own staff and advisors. Despite leadership's attempts to downplay the controversy, doubts now surround standards for accelerated approval.

    Editorial
Top of page ⤴

News

Top of page ⤴

Correction

Top of page ⤴

Data Page

Top of page ⤴

News Feature

  • Detecting cancer by liquid biopsy is attracting a lot of money and hype. Can it deliver on its promise to transform oncology? Sarah Webb reports.

    • Sarah Webb
    News Feature
Top of page ⤴

Bioentrepreneur

  • Is it worth your time to seek overseas investors?

    • Rogier W Rooswinkel
    • Daan S W Berbers
    • Sander van Deventer
    Bioentrepreneur
Top of page ⤴

Correspondence

Top of page ⤴

Commentary

  • To ensure global food security for all, the adoption of crop improvement technologies is no longer just an option—it is an imperative.

    • Richard B Flavell

    Nature Outlook:

    Commentary
Top of page ⤴

Feature

Top of page ⤴

Patents

Top of page ⤴

News & Views

Top of page ⤴

Analysis

Top of page ⤴

Perspective

Top of page ⤴

Review Article

Top of page ⤴

Article

Top of page ⤴

Resource

Top of page ⤴

Erratum

Top of page ⤴

Careers and Recruitment

Top of page ⤴

In This Issue

Top of page ⤴

Search

Quick links